Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Dr Reddys Laboratories (RDY) over the last 14 years, with Q3 2025 value amounting to $536.0 million.

  • Dr Reddys Laboratories' Other Accumulated Expenses rose 736.03% to $536.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.0 million, marking a year-over-year increase of 736.03%. This contributed to the annual value of $538.2 million for FY2025, which is 385.14% up from last year.
  • Latest data reveals that Dr Reddys Laboratories reported Other Accumulated Expenses of $536.0 million as of Q3 2025, which was up 736.03% from $525.3 million recorded in Q1 2025.
  • Dr Reddys Laboratories' 5-year Other Accumulated Expenses high stood at $536.0 million for Q3 2025, and its period low was $412.3 million during Q3 2021.
  • Over the past 5 years, Dr Reddys Laboratories' median Other Accumulated Expenses value was $466.1 million (recorded in 2023), while the average stood at $470.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 133.79% in 2022, then surged by 1232.08% in 2024.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Other Accumulated Expenses stood at $412.3 million in 2021, then rose by 1.34% to $417.8 million in 2022, then grew by 6.39% to $444.5 million in 2023, then grew by 12.32% to $499.3 million in 2024, then grew by 7.36% to $536.0 million in 2025.
  • Its Other Accumulated Expenses was $536.0 million in Q3 2025, compared to $525.3 million in Q1 2025 and $499.3 million in Q3 2024.